Table 1.
Comparative demographics between chemoresistant and platinium sensitive patients
| Platinium resistant subgroup (n = 16) | Platinium sensitive subgroup (n = 12) | p-value | |
|---|---|---|---|
| Age (years) | 60.4 (± 12.1) | 63.8 (± 6.6) | 0.38 |
| BMI | 24.1 (± 4.6) | 23.8 (± 3.2) | 0.82 |
| CA 125 (U/ml) at baseline | 2600 (± 3098.2) | 1235 (± 1252.0) | 0.16 |
| Histological type | |||
| Serous | 87.5% (n = 14) | 66.7% (n = 8) | 0.58 |
| Undifferentiated | 6.25% (n = 1) | 16.7% (n = 2) | |
| Mucinous | 0 | 8.3% (n = 1) | |
| Endometrioid | 6.25% (n = 1) | 8.3% (n = 1) | |
| FIGO stage | |||
| IIIC | 81.2% (n = 13) | 100% (n = 12) | 0.11 |
| IV | 18.8% (n = 3) | 0 | |
| Count of NAC courses | 4 (3–6) | 3 (3–7) | 0.34 |
| Total count of chemotherapy courses | 7 (3–12) | 6 (3–9) | 0.15 |
| Delay between diagnosis and surgical debulking (months) | 4.3 (± 1.2) | 3.9 (± 1.2) | 0.43 |
| Completeness of cytoreduction scorea | |||
| CC-0 | 68.7% (n = 11) | 83.4% (n = 10) | 0.38 |
| CC-1 | 6.3% (n = 1) | 0 | |
| CC-2 | 18.7% (n = 3) | 8.3% (n = 1) | |
| CC-3 | 6.3% (n = 1) | 8.3% (n = 1) | |
| Mean IL8 expression on tumor sample | 31.3% | 11.0% | 0.004** |
| Duration of surgical procedure (min) | 428 (± 139) | 310 (± 82) | 0.07 |
| Overall survival (months) | 31.9 | 78.9 | < 10−4*** |
BMI body mass index, NAC neoadjuvant chemotherapy
aA CC-0 score indicates a complete disease removal; a CC-1 score indicates that tumor nodules persisting after cytoreduction were < 2.5 mm in diameter; a CC-2 score indicates residual tumor nodules between 2.5 mm and 25 mm in diameter; a CC-3 score indicates residual tumor nodules > 25 mm in diameter or a confluence of unresectable tumor nodules at any site within the abdomen or pelvis